Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2.
about
GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1Genetic perspective on the role of the autophagy-lysosome pathway in Parkinson diseaseLeucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADPInhibition of excessive mitochondrial fission reduced aberrant autophagy and neuronal damage caused by LRRK2 G2019S mutationLRRK2 phosphorylates tubulin-associated tau but not the free molecule: LRRK2-mediated regulation of the tau-tubulin association and neurite outgrowthThreonine 56 phosphorylation of Bcl-2 is required for LRRK2 G2019S-induced mitochondrial depolarization and autophagyFunctional interaction of Parkinson's disease-associated LRRK2 with members of the dynamin GTPase superfamilyInterplay of LRRK2 with chaperone-mediated autophagyUnbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson diseaseDisrupted autophagy leads to dopaminergic axon and dendrite degeneration and promotes presynaptic accumulation of α-synuclein and LRRK2 in the brainMutant LRRK2 elicits calcium imbalance and depletion of dendritic mitochondria in neuronsEvaluation of Models of Parkinson's DiseaseThe associations between Parkinson's disease and cancer: the plot thickensCurrent understanding of LRRK2 in Parkinson's disease: biochemical and structural features and inhibitor designParkinson's disease, insulin resistance and novel agents of neuroprotectionHeterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implicationsIs inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease?High LRRK2 levels fail to induce or exacerbate neuronal alpha-synucleinopathy in mouse brainProgressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in miceNo dopamine cell loss or changes in cytoskeleton function in transgenic mice expressing physiological levels of wild type or G2019S mutant LRRK2 and in human fibroblastsLeucine-rich repeat kinase 2 (LRRK2)-deficient rats exhibit renal tubule injury and perturbations in metabolic and immunological homeostasisDysregulation of autophagy and mitochondrial function in Parkinson's diseaseLRRK2 at the interface of autophagosomes, endosomes and lysosomesLRRK2 inhibitors and their potential in the treatment of Parkinson's disease: current perspectivesParkinson's disease: animal models and dopaminergic cell vulnerabilityPathogenic Parkinson's disease mutations across the functional domains of LRRK2 alter the autophagic/lysosomal response to starvationPARK9-associated ATP13A2 localizes to intracellular acidic vesicles and regulates cation homeostasis and neuronal integrityInhibition of LRRK2 kinase activity stimulates macroautophagyProtective LRRK2 R1398H Variant Enhances GTPase and Wnt Signaling Activity.Transgenic LRRK2 (R1441G) rats-a model for Parkinson disease?Animal models of Parkinson's disease: vertebrate geneticsNeurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2.Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegenerationERKed by LRRK2: a cell biological perspective on hereditary and sporadic Parkinson's disease.LRRK2 levels in immune cells are increased in Parkinson's diseaseParkinson's disease-linked mutations in VPS35 induce dopaminergic neurodegeneration.Mutant LRRK2 enhances glutamatergic synapse activity and evokes excitotoxic dendrite degenerationLeucine-rich repeat kinase 2 for beginners: six key questions.Common pathogenic effects of missense mutations in the P-type ATPase ATP13A2 (PARK9) associated with early-onset parkinsonismRole of LRRK2 kinase activity in the pathogenesis of Parkinson's disease.
P2860
Q21144926-724F6847-19EA-434E-870C-1377C98A6E9DQ22242985-D9096473-AD7E-443A-8D99-5D948835FBE7Q24293723-0D68382A-015E-4979-8A96-6EA3A10EF5FFQ24297033-17303133-CE8A-46FC-AB42-AC695CEFDB41Q24304347-398AB51F-7D99-4CE4-AB1F-897DB5523007Q24307769-6DBE5C14-11BD-4251-846B-6BBDA85A5A58Q24310218-DACFE2B1-835F-42AD-A7BF-64E3B15E668AQ24322747-97290B79-DB31-4B87-8EE4-30FAE8EAFB5DQ24336432-99E436EC-9291-4252-99A5-8491B752A8BBQ24599233-7455070E-DFFF-4CDB-9A89-C621A3B3B1E5Q24628425-6841F27B-D3D3-4711-A607-D0678879969BQ26772843-AAD676F3-08C3-490D-B83E-B82A2B644193Q26778641-7B4C49E6-62FC-4DDB-8C9C-806B62A4C1FCQ26827527-60772C14-CF69-40AD-ABFD-EBC7A0064BB3Q26853311-BD73CCB6-316B-4416-B5F5-5B5E309850BFQ27013695-937BA7D1-8BEC-4ABA-862C-60940E6DA012Q27026262-FEF3D018-1BC6-4CC6-B584-42F080DB333FQ27303568-BFD26D18-7BCD-4CB6-AAF3-8669772C4996Q27308060-91E0FDEE-0456-48D0-A0ED-3A42D9614942Q27312569-580105DC-365F-4B73-B0BE-B81DDCB1E427Q27315276-1BB18D9E-7806-4085-9903-2FBA3991BE9AQ28071890-A0BCF738-9E8B-4C01-BCAC-36FA278BF626Q28078248-B0B1DD49-B8CB-4606-977E-09D3343EF426Q28078899-FB50DFB4-43DC-4143-9181-42B1D0D0F4D5Q28080503-25E03AA7-8B79-416C-A028-8AD201AAB3BFQ28115231-D4B3781C-73D2-4AE9-92B7-99844608F6CAQ28117134-55A82A56-A6E2-491E-A322-A12DE644004BQ28118311-34E309BC-97AF-44CC-BEBE-407F954A1A91Q29347547-BD6818F5-0727-4ED2-96DA-636EA2A0F7D0Q30410927-A9A7ECCD-27A3-4F23-A344-D6F8297E3015Q30429583-36F8DBBB-B6AC-49C1-AA99-4EAF1CCC4603Q30454029-BB254721-ABF9-4D40-87A9-AC84CAEBC3C3Q30653185-664714F1-77D2-4FB6-A6A9-3AF46B4978B6Q33593798-151B31C4-E9E4-4D61-B98D-7FC6D4964FFDQ33765746-0C0495B7-DFD9-4BE9-A7F0-F6E70CF1DC7DQ33991769-C329B342-8732-4BAC-9A39-FC786999A9D1Q34086842-BA52C373-11A6-4A6A-8067-7A4F9C5857C8Q34259058-66B84245-6710-4958-A622-03684870D9EBQ34286404-934B3978-DD8B-4388-9D05-4DF2CA6F071EQ34300430-209CCB84-107B-43DC-A4BF-51C71A0522CF
P2860
Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Dopaminergic neuronal loss, re ...... expressing G2019S mutant LRRK2
@nl
Dopaminergic neuronal loss, re ...... xpressing G2019S mutant LRRK2.
@ast
Dopaminergic neuronal loss, re ...... xpressing G2019S mutant LRRK2.
@en
Dopaminergic neuronal loss, re ...... xpressing G2019S mutant LRRK2.
@en-gb
type
label
Dopaminergic neuronal loss, re ...... expressing G2019S mutant LRRK2
@nl
Dopaminergic neuronal loss, re ...... xpressing G2019S mutant LRRK2.
@ast
Dopaminergic neuronal loss, re ...... xpressing G2019S mutant LRRK2.
@en
Dopaminergic neuronal loss, re ...... xpressing G2019S mutant LRRK2.
@en-gb
altLabel
Dopaminergic Neuronal Loss, Re ...... Expressing G2019S Mutant LRRK2
@en
prefLabel
Dopaminergic neuronal loss, re ...... expressing G2019S mutant LRRK2
@nl
Dopaminergic neuronal loss, re ...... xpressing G2019S mutant LRRK2.
@ast
Dopaminergic neuronal loss, re ...... xpressing G2019S mutant LRRK2.
@en
Dopaminergic neuronal loss, re ...... xpressing G2019S mutant LRRK2.
@en-gb
P2093
P2860
P50
P921
P3181
P1433
P1476
Dopaminergic neuronal loss, re ...... xpressing G2019S mutant LRRK2.
@en
P2093
Bobby Thomas
Brian M Lin
Darren J Moore
Deborah A Swing
J Michael McCaffery
Jaekwang Kim
João Paulo L Daher
Juan C Troncoso
Klodjan Stafa
Lichuan Yang
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0018568
P407
P50
P577
2011-04-06T00:00:00Z